Health Care·Biotechnology·$4.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.30 | N/A | -41.92% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.30 | N/A | -41.92% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about their pipeline and ongoing projects. They acknowledged the difficulties faced but remain focused on future developments.
Management highlighted ongoing progress in their clinical trials.
They emphasized the importance of long-term goals despite current challenges.
The earnings report shows that CRISPR Therapeutics missed expectations on EPS, which may raise concerns among investors. However, the stock reacted positively, gaining 1.96%, likely due to management's focus on long-term progress in their clinical trials. Investors may be encouraged by the company's ongoing developments despite the EPS miss.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
EQUINOR ASA ADR
Jul 24, 2020